OmniAb Q4 revenue falls 22%, misses expectations

Overview

• Biotech platform's Q4 revenue fell 22% yr/yr, missing analyst expectations

• Net loss for Q4 increased to $14.2 mln from $13.1 mln yr/yr

• Company entered new license agreements, including with Dana Farber Cancer Institute

Outlook

• OmniAb expects 2026 revenue between $25 mln and $30 mln

• Company forecasts 2026 operating expenses between $80 mln and $85 mln

• OmniAb anticipates ending 2026 with cash and equivalents of $30 mln to $35 mln

Result Drivers

• REVENUE DECLINE - Q4 revenue decreased due to lower license and service revenue, partially offset by milestone and royalty revenue increases

• NEW TECHNOLOGY LAUNCH - Launch of OmniUltra and interest in xPloration program contributed to business growth

Company press release: ID:nBw4gkhFpa

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for OmniAb Inc is $8.00, about 362.4% above its March 3 closing price of $1.73

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.